Treatment of BRL 28500 (clavulanic acid-ticarcillin) for infections in patients with hematological diseases

Keisuke Toyama; Shinichiro Okamoto; Hiroshi Uchida; Yasuhiko Ando

doi:10.11250/chemotherapy1953.34.Supplement4_452

Treatment of BRL 28500 (clavulanic acid-ticarcillin) for infections in patients with hematological diseases

Keisuke Toyama, Shinichiro Okamoto, Hiroshi Uchida, Yasuhiko Ando

Research output: Contribution to journal › Article › peer-review

Abstract

BRL 28500, ticarcillin combined with clavulanic acid, was evaluated clinically for infections in 5 patients with hematological diseases. BRL 28500 was administrated by one-hour drip intravenous infusion at a daily dose of 12.8g for 4 to 10 days. Duration of BRL 28500 therapy was determined according to the patient's condition. Five cases consisted of 2 cases with possible septicemia, 2 cases with pneumonia and/or possible septicemia and one with cellulitis. The clinical response to BRL 28500 therapy of possible septicemia was good in one case, but all other cases did not respond to BRL 28500. No significant side effect was observed after the administration of BRL 28500.

Original language	English
Pages (from-to)	452-454
Number of pages	3
Journal	Chemotherapy
Volume	34
DOIs	https://doi.org/10.11250/chemotherapy1953.34.Supplement4_452
Publication status	Published - 1986
Externally published	Yes

ASJC Scopus subject areas

Pharmacology (medical)
Infectious Diseases
Pharmacology
Drug Discovery
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.11250/chemotherapy1953.34.Supplement4_452

Cite this

@article{1f80786ff43b4ec49b82d3c205276ac1,

title = "Treatment of BRL 28500 (clavulanic acid-ticarcillin) for infections in patients with hematological diseases",

abstract = "BRL 28500, ticarcillin combined with clavulanic acid, was evaluated clinically for infections in 5 patients with hematological diseases. BRL 28500 was administrated by one-hour drip intravenous infusion at a daily dose of 12.8g for 4 to 10 days. Duration of BRL 28500 therapy was determined according to the patient's condition. Five cases consisted of 2 cases with possible septicemia, 2 cases with pneumonia and/or possible septicemia and one with cellulitis. The clinical response to BRL 28500 therapy of possible septicemia was good in one case, but all other cases did not respond to BRL 28500. No significant side effect was observed after the administration of BRL 28500.",

author = "Keisuke Toyama and Shinichiro Okamoto and Hiroshi Uchida and Yasuhiko Ando",

year = "1986",

doi = "10.11250/chemotherapy1953.34.Supplement4_452",

language = "English",

volume = "34",

pages = "452--454",

journal = "Chemotherapy",

issn = "0009-3165",

}

TY - JOUR

T1 - Treatment of BRL 28500 (clavulanic acid-ticarcillin) for infections in patients with hematological diseases

AU - Toyama, Keisuke

AU - Okamoto, Shinichiro

AU - Uchida, Hiroshi

AU - Ando, Yasuhiko

PY - 1986

Y1 - 1986

N2 - BRL 28500, ticarcillin combined with clavulanic acid, was evaluated clinically for infections in 5 patients with hematological diseases. BRL 28500 was administrated by one-hour drip intravenous infusion at a daily dose of 12.8g for 4 to 10 days. Duration of BRL 28500 therapy was determined according to the patient's condition. Five cases consisted of 2 cases with possible septicemia, 2 cases with pneumonia and/or possible septicemia and one with cellulitis. The clinical response to BRL 28500 therapy of possible septicemia was good in one case, but all other cases did not respond to BRL 28500. No significant side effect was observed after the administration of BRL 28500.

AB - BRL 28500, ticarcillin combined with clavulanic acid, was evaluated clinically for infections in 5 patients with hematological diseases. BRL 28500 was administrated by one-hour drip intravenous infusion at a daily dose of 12.8g for 4 to 10 days. Duration of BRL 28500 therapy was determined according to the patient's condition. Five cases consisted of 2 cases with possible septicemia, 2 cases with pneumonia and/or possible septicemia and one with cellulitis. The clinical response to BRL 28500 therapy of possible septicemia was good in one case, but all other cases did not respond to BRL 28500. No significant side effect was observed after the administration of BRL 28500.

UR - http://www.scopus.com/inward/record.url?scp=0022981924&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022981924&partnerID=8YFLogxK

U2 - 10.11250/chemotherapy1953.34.Supplement4_452

DO - 10.11250/chemotherapy1953.34.Supplement4_452

M3 - Article

AN - SCOPUS:0022981924

SN - 0009-3165

VL - 34

SP - 452

EP - 454

JO - Chemotherapy

JF - Chemotherapy

ER -

Treatment of BRL 28500 (clavulanic acid-ticarcillin) for infections in patients with hematological diseases

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this